glp 1 studies GLP-1 Receptor Agonist Market Size & Analysis, 2026-2033 Discover How GLP-1 Trials Are

Discover how GLP-1 and GLP-1/GIP therapies (semaglutide and tirzepatide) influence body composition

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan

CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.

Serena Williams GLP-1 disclosure may shift obesity conversations, though treatment requires a holistic approach, Northeastern experts say.

If you're thinking about how to manage GLP-1 costs while improving outcomes, wed encourage you to explore the data and the broader strategy behind it

The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery